08:42 AM EST, 11/24/2025 (MT Newswires) -- NeuroPace ( NPCE ) said Monday that Medicare reimbursement will "substantially increase" for its RNS neurostimulator implant and replacement procedures.

The physician fee schedule for 2026 increases professional payment for neurosurgeons by about 43% for the initial implant and 45% for replacement procedures, the company said.

Separately, the outpatient prospective payment system final rule increases average hospital medicare reimbursement by 47% starting Jan. 1, 2026.

Shares of NeuroPace ( NPCE ) were up by 2% in recent Monday premarket activity.